Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2016

05.07.2016 | Original Article

Analysis of positron emission tomography/computed tomography in patients to differentiate between malignant transformation of endometrioma and endometrioma

verfasst von: Soshi Kusunoki, Tsuyoshi Ota, Hiroshi Kaneda, Miki Kimura, Yasuhisa Terao, Satoru Takeda

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Of those patients who undergo open surgery for a suspicion of malignant transformation of endometrioma (MTOE) due to solid nodule enhancement identified by contrast-enhanced magnetic resonance imaging (MRI), some benign endometrioma cases are included. The aim of this retrospective study was to determine the value and diagnostic accuracy of positron emission tomography/computed tomography (PET/CT) using 18-fluoro-2-deoxy-d-glucose (FDG) to differentiate between MTOE and endometrioma.

Patients and methods

We retrospectively analyzed 1599 consecutive patients who underwent laparoscopic surgery for the diagnosis of endometrioma preoperatively and 31 patients who underwent open surgery for a suspicion of MTOE preoperatively from January 2003 to December 2011. We analyzed the age, serum CA125 levels, and MRI findings of the patients and calculated the optimal cut-off value for PET/CT using receiver operating characteristic curve analysis.

Results

Of the 1,599 patients who underwent laparoscopic surgery for a suspicion of endometrioma preoperatively, malignancy was identified in one (0.062 %) patient. Of the 31 patients who underwent open surgery for a suspicion of MTOE preoperatively, 11 were diagnosed with endometrioma (false positive group) and 20 with MTOE stage I (positive group). Age, tumor size, presence of shading on MRI and maximum standardized uptake values (SUVmax) on PET/CT were significantly different between the two groups. A SUVmax cut-off >4.0 is capable of excluding endometrioma cases, with 75 % sensitivity and 100 % specificity (area under the curve 90 %).

Conclusion

PET/CT is a good diagnostic tool for MTOE using the optimal SUVmax cut-off of 4.0 (75 % sensitivity and 100 % specificity).
Literatur
1.
Zurück zum Zitat Harada T, Iwabe T, Terakawa N (2001) Role of cytokines in endometriosis. Fertil Steril 76:1–10CrossRefPubMed Harada T, Iwabe T, Terakawa N (2001) Role of cytokines in endometriosis. Fertil Steril 76:1–10CrossRefPubMed
2.
Zurück zum Zitat Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43CrossRefPubMed Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43CrossRefPubMed
3.
Zurück zum Zitat Tanaka Y, Yoshizako T, Nishida M et al (2000) Ovarian carcinoma in patients with endometriosis: MR imaging findings. Am J Roentgenol 175:1423–1430CrossRef Tanaka Y, Yoshizako T, Nishida M et al (2000) Ovarian carcinoma in patients with endometriosis: MR imaging findings. Am J Roentgenol 175:1423–1430CrossRef
4.
Zurück zum Zitat Scott RB (1953) Malignant changes in endometriosis. Obstet Gynecol 2:283–289PubMed Scott RB (1953) Malignant changes in endometriosis. Obstet Gynecol 2:283–289PubMed
5.
Zurück zum Zitat Taniguchi F, Harada T, Kobayashi H et al (2014) Clinical characteristics of patients in Japan with ovarian cancer presumably arising from ovarian endometrioma. Gynecol Obstet Invest 77:104–110CrossRefPubMed Taniguchi F, Harada T, Kobayashi H et al (2014) Clinical characteristics of patients in Japan with ovarian cancer presumably arising from ovarian endometrioma. Gynecol Obstet Invest 77:104–110CrossRefPubMed
6.
Zurück zum Zitat Kawaguchi R, Tsuji Y, Haruta S et al (2008) Clinicopathologic features of ovarian cancer in patients with ovarian endometrioma. J Obstet Gynaecol Res 34:872–877CrossRefPubMed Kawaguchi R, Tsuji Y, Haruta S et al (2008) Clinicopathologic features of ovarian cancer in patients with ovarian endometrioma. J Obstet Gynaecol Res 34:872–877CrossRefPubMed
7.
Zurück zum Zitat Kobayashi H, Sumimoto K, Kitanaka T et al (2008) Ovarian endometrioma-risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol 138:187–193CrossRefPubMed Kobayashi H, Sumimoto K, Kitanaka T et al (2008) Ovarian endometrioma-risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol 138:187–193CrossRefPubMed
8.
Zurück zum Zitat Nam EJ, Yun MJ, Oh YT et al (2010) Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol 116:389–394CrossRefPubMed Nam EJ, Yun MJ, Oh YT et al (2010) Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol 116:389–394CrossRefPubMed
9.
Zurück zum Zitat Karlan BY, Hawkins R, Hoh C et al (1993) Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-d-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 51:175–181CrossRefPubMed Karlan BY, Hawkins R, Hoh C et al (1993) Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-d-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 51:175–181CrossRefPubMed
10.
Zurück zum Zitat Rieber A, Nussle K, Stohr I et al (2001) Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 177:123–129CrossRef Rieber A, Nussle K, Stohr I et al (2001) Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 177:123–129CrossRef
11.
Zurück zum Zitat Lerman H, Metser U, Grisaru D et al (2004) Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre– and postmenopausal patients: assessment by PET/CT. J Nucl Med 45:266–271PubMed Lerman H, Metser U, Grisaru D et al (2004) Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre– and postmenopausal patients: assessment by PET/CT. J Nucl Med 45:266–271PubMed
12.
Zurück zum Zitat Nishizawa S, Inubushi M, Okada H (2005) Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 32:549–556CrossRefPubMed Nishizawa S, Inubushi M, Okada H (2005) Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 32:549–556CrossRefPubMed
Metadaten
Titel
Analysis of positron emission tomography/computed tomography in patients to differentiate between malignant transformation of endometrioma and endometrioma
verfasst von
Soshi Kusunoki
Tsuyoshi Ota
Hiroshi Kaneda
Miki Kimura
Yasuhisa Terao
Satoru Takeda
Publikationsdatum
05.07.2016
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1013-x

Weitere Artikel der Ausgabe 6/2016

International Journal of Clinical Oncology 6/2016 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.